Clarus Therapeutics, Inc.
14
1
1
13
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 5/100
0.0%
0 terminated/withdrawn out of 14 trials
100.0%
+13.5% vs industry average
36%
5 trials in Phase 3/4
85%
11 of 13 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Testosterone Treatment in Men With Chronic Kidney Disease
Role: collaborator
Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer
Role: collaborator
Patient Satisfaction After Switching to Oral Testosterone Undecanoate
Role: collaborator
Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men
Role: lead
Pharmacokinetic Study of Oral Testosterone (T) Ester Formulations in Hypogonadal Men
Role: lead
Pharmacokinetic Study to Determine Time to Steady-state
Role: lead
Study to Determine the Effect of Food on the Absorption of an Oral Testosterone Undecanoate Formulation
Role: lead
Assessment of Blood From Men Receiving Oral TU in Various Collection Tubes
Role: lead
Pilot Pharmacokinetic Study of Oral Testosterone Ester Formulations in Hypogonadal Men
Role: lead
Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men
Role: lead
The Effect of Various Amounts of Fat on PK of Oral Testosterone Undecanoate
Role: lead
Phlebotomy Study of Testosterone Undecanoate
Role: lead
A Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men
Role: lead
Safety and Efficacy Trial of Testosterone Undecanoate
Role: lead
All 14 trials loaded